Gene Annotation and Drug Target Discovery in Candida albicans with a Tagged Transposon Mutant Collection
Journal Article
·
· PLoS Pathogens
- Stanford University, CA (United States); DOE/OSTI
- Stanford Genome Technology Center, Palo Alto, CA (United States)
- Stanford University, CA (United States); Stanford Genome Technology Center, Palo Alto, CA (United States)
- University of Toronto, ON (Canada); Donnelley Center for Cellular and Biomolecular Research, Toronto, ON (Canada)
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Univ. of Toronto, ON (Canada); Donnelley Center for Cellular and Biomolecular Research, Toronto, ON (Canada)
Candida albicans is the most common human fungal pathogen, causing infections that can be lethal in immunocompromised patients. Although Saccharomyces cerevisiae has been used as a model for C. albicans, it lacks C. albicans’ diverse morphogenic forms and is primarily non-pathogenic. Comprehensive genetic analyses that have been instrumental for determining gene function in S. cerevisiae are hampered in C. albicans, due in part to limited resources to systematically assay phenotypes of loss-of-function alleles. Here, we constructed and screened a library of 3633 tagged heterozygous transposon disruption mutants, using them in a competitive growth assay to examine nutrient- and drug-dependent haploinsufficiency. We identified 269 genes that were haploinsufficient in four growth conditions, the majority of which were condition-specific. These screens identified two new genes necessary for filamentous growth as well as ten genes that function in essential processes. We also screened 57 chemically diverse compounds that more potently inhibited growth of C. albicans versus S. cerevisiae. For four of these compounds, we examined the genetic basis of this differential inhibition. Notably, Sec7p was identified as the target of brefeldin A in C. albicans screens, while S. cerevisiae screens with this compound failed to identify this target. We also uncovered a new C. albicans-specific target, Tfp1p, for the synthetic compound 0136-0228. These results highlight the value of haploinsufficiency screens directly in this pathogen for gene annotation and drug target identification.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- Canadian Cancer Society; National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH); Stanford Genome Training Program; USDOE Office of Science (SC), Biological and Environmental Research (BER)
- Grant/Contract Number:
- AC02-05CH11231
- OSTI ID:
- 1627897
- Journal Information:
- PLoS Pathogens, Journal Name: PLoS Pathogens Journal Issue: 10 Vol. 6; ISSN 1553-7374
- Publisher:
- Public Library of ScienceCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Adaptation to the dietary sugar D-tagatose via genome instability in polyploid Candida albicans cells
A role for Candida albicans superoxide dismutase enzymes in glucose signaling
CRISPR-GRIT: Guide RNAs with Integrated Repair Templates Enable Precise Multiplexed Genome Editing in the Diploid Fungal Pathogen Candida albicans
Journal Article
·
Thu Apr 08 20:00:00 EDT 2021
· G3
·
OSTI ID:2471774
A role for Candida albicans superoxide dismutase enzymes in glucose signaling
Journal Article
·
Sun Jan 14 23:00:00 EST 2018
· Biochemical and Biophysical Research Communications
·
OSTI ID:23127542
CRISPR-GRIT: Guide RNAs with Integrated Repair Templates Enable Precise Multiplexed Genome Editing in the Diploid Fungal Pathogen Candida albicans
Journal Article
·
Mon Oct 21 20:00:00 EDT 2024
· The CRISPR Journal
·
OSTI ID:2479302